

PORTFOLIO MANAGER COMMENTARY

What a difference one quarter makes. In our previous commentary we wrote that the MSCI Emerging Index fell almost 20% from mid April to late May. This past quarter saw the index rise 18.2% and we are pleased that the fund outperformed the benchmark by 2.9% during this period. We would however rather be evaluated over longer and more meaningful time periods. In this regard, the fund has generated an annualised dollar return of 10.3% over more than 2 years since the fund was launched, and in doing so has outperformed the MSCI Emerging Markets Index by over 6% p.a.

There was only one name change in the top ten holdings of the fund during the quarter. Petrobras (still a top 12 position) was replaced by Banco Santander Brazil, a holding which we've added to substantially over the period. The long-term fundamentals for the banking sector in Brazil are very positive in our view (high GDP growth rates, rising disposable incomes, declining unemployment and low banking penetration). Within the sector we believe that Banco Santander Brazil is amongst the best managed banks with the most potential to increase ROE's over time (toward the 20% level from the current 12% level). The bank is also very well capitalised, in fact overcapitalised in our view, and as such has plenty of room to grow their loan book. The bank trades on 11x what we believe it will earn over the next year, with a 5% dividend yield, which we believe is very attractive.

China Unicom, C&O Pharmaceutical and Colgate Palmolive were all introduced into the fund. We sold holdings in Telefonica on concerns that they would end up overpaying for Brasilcel (a Brazilian telecommunications company), Anadolu Efes (Turkish listed brewer and beverage company) as it reached our fair value and Brazilian education company Sistema which received an offer for their learning system division by the Pearson Group.

China Unicom is a provider of both fixed and mobile telecommunication products, that is trading on 8x our estimate of normalised free cash flow. While the traditional fixed line voice offering is in decline, we believe an opportunity lies in their broadband and data offering. In 2009, Chinese internet penetration reached 19%: meaning 2 out of every 10 people in China have access to the internet. Korea (an example of a more developed Asian country) reached 19% penetration in 1999. Current penetration for the US and Korea are both around 72%, while penetration in China is 25% today. Astonishingly, there are already more internet users in China (approaching 400 million) than there are in the US (220 million), yet China only has internet penetration of 25% compared to 72% in the US. China doesn't need to reach 70% penetration (US and Korea levels) for there to be significant growth ahead – a move from 25% to 50% penetration would add another 400 million internet users. Besides China Unicom, the fund also has a number of other large holdings in internet companies (portals and/or online gaming companies) that will benefit from increasing internet usage in China including Naspers (through its Tencent stake), Netease.com, Sohu.com and Perfect World. The latter 3 all have large net cash balances (ranging from 15% to 25% of current market caps) and are trading on low double-digit ratings excluding the net cash, which we believe is very attractive given expected double-digit earnings growth rates for a number of years ahead.

C&O Pharmaceutical is a small Singapore-listed Chinese generic pharmaceutical company which we believe has been overlooked by investors. The Chinese healthcare market is one of the most underserved in the world with 50% of urban residents not having sufficient healthcare and 30% of the rural population not having any form of healthcare. The 4-2-1 (grandparents, parents and child) family structure means that China has a rapidly aging population requiring increased medical spend. As part of their plan to combat the impact of the global recession the state's healthcare spend was increased substantially to US\$130 billion over the 2009-2012 period. The market for pharmaceutical products has grown in excess of 20% for the past five years. C&O core operations are focused on the production and sale of finished goods. The product portfolio include their own proprietary products and the exclusive distribution under licence for Hong Kong and Japanese pharmaceutical companies. The business is a strong cash generator and continues to distribute excess capital to shareholders having declared two special dividends this year. The share trades 10x this year's earnings with a 4% dividend yield.

The inflows into emerging market equities have resulted in a number of stocks in our universe trading above what we believe is fair value. Whilst we are still uncovering selected very good value within emerging markets, we do not restrict ourselves to companies listed on emerging market exchanges – we also consider those listed on developed exchanges which today generate a large portion of their earnings (at least 40%+) from emerging markets. Colgate Palmolive is an example where 50% of revenues are generated from emerging markets. We initially analysed Colgate Palmolive India (51%-held subsidiary of the US-based mothership), but concluded that it was too expensive and did not provide us with the margin of safety that we insist on. This however led us to take a detailed look at the holding company (US-listed Colgate Palmolive). The business owns a collection of great brands that dominate their categories in many cases. Operating margins are consistently over 20% and due to this as well as high asset turns the business generates ROE's north of 70%. Earnings per share has grown by 10.6% p.a. over the past 20 years and dividends per share by 10.4% over the same time period. Today one can buy this high quality business on just 14x what we believe the business will earn over the next year, which we believe provides an attractive risk-reward payoff.

Portfolio managers

Gavin Joubert, Mark Butler and Suhail Suleman

CORONATION GLOBAL EMERGING MARKETS FUND


A sub-fund of the Coronation Global Opportunities Fund domiciled in Ireland
as at 30 September 2010

Currency	USD
Minimum Investment	US\$15,000.00
Launch date	14 July 2008
Portfolio manager/s	Gavin Joubert, Mark Butler and Suhail Suleman
Annual management fee	1.1%
Annual outperformance	15% of returns above MSCI Emerging Markets Index with 2% cap
Fund domicile	Ireland
Listing	Irish Stock Exchange

Fund size	US\$356.29 million
Benchmark	MSCI Emerging Markets Index
Liquidity	Daily
Redemption period	1 business day preceding dealing day
Redemption payout	2 business days after dealing day
Bloomberg	CORGEMA ID
ISIN	IE00B2RGGZ18
SEDOL	B2RGGZ1

PERFORMANCE AND RISK STATISTICS¹

GROWTH OF A US\$100,000 INVESTMENT



PERFORMANCE FOR VARIOUS PERIODS

	Fund	Benchmark	Outperformance
Since Inception (unannualised)	24.31%	9.58%	14.73%
Since Inception (annualised)	10.33%	4.22%	6.11%
Latest 1 year (annualised)	17.38%	20.54%	(3.17)%
Year to date	7.34%	11.02%	(3.68)%
2009	87.08%	79.02%	8.06%
2008	(38.10)%	(44.87)%	6.77%

RISK STATISTICS SINCE INCEPTION

	Fund	Benchmark
Annualised Deviation	35.36%	35.21%
Sharpe Ratio	0.03	(0.14)
Maximum Gain	99.43%	56.31%
Maximum Drawdown	(49.52)%	(51.41)%
Positive Months	59.26%	55.56%

MONTHLY PERFORMANCE RETURNS

	Jan	Feb	Mar	Apr	May	Jun	Jul	Aug	Sep	Oct	Nov	Dec	YTD
Fund 2010	(6.6)%	1.2%	5.4%	0.1%	(8.3)%	(3.0)%	12.0%	(1.4)%	9.5%				7.3%
Fund 2009	(9.9)%	(4.8)%	13.7%	19.2%	18.9%	2.5%	10.1%	2.0%	7.5%	(0.1)%	4.0%	5.3%	87.1%
Fund 2008							5.2%	(4.8)%	(15.7)%	(26.4)%	(7.9)%	8.0%	(38.1)%

INVESTMENT PHILOSOPHY

- We strive to buy shares that are trading well below what we believe the business is worth (valuation-driven approach).
- In valuing a business we focus on normalised earnings/free cash flow as opposed to current earnings.
- A long-term time horizon (5 year +) is used.

PORTFOLIO DETAIL

EFFECTIVE ASSET ALLOCATION EXPOSURE

Country	30 Sep 2010
Equities	99.19%
China	21.52%
Brazil	13.98%
South Africa	11.20%
Israel	6.26%
Russia	6.23%
Turkey	5.70%
Greece	5.01%
United States	4.61%
Mexico	3.60%
Korea	3.16%
Other	17.92%
Cash	0.81%
ZAR	1.99%
USD	0.22%
Other	(1.40)%

TOP 10 HOLDINGS

As at 30 Sep 2010	% of Fund
MTN Group Ltd (South Africa)	5.66%
Naspers Ltd (South Africa)	5.53%
OAO Gazprom Reg (Russia)	5.27%
Turkiye Garanti Bankasi (Turkey)	4.92%
Teva Pharmaceutical Industries Ltd (Israel)	4.04%
Netease.com Inc (China)	3.78%
Sohu.com Inc (China)	3.67%
China Dongxiang Group Co (China)	3.14%
Banco Santander Brasil (Brazil)	3.11%
Bank of Baroda (India)	2.85%

INVESTMENT OBJECTIVE

The fund has an objective of outperforming the MSCI Emerging Markets Index over a 3 – 5 year period through investing in what we believe to be the most undervalued shares within the global emerging markets universe. The fund will typically be fully invested in equities at all times (90% + equity exposure).

The document has been prepared by Coronation Asset Management (Pty) Limited, an authorised Financial Services Provider in South Africa and approved by Coronation International Limited ("CIL") for the purposes of section 21 of the Financial Services and Markets Act 2000. CIL is authorised and regulated by the Financial Services Authority ("the FSA"). To the extent that this document is issued in the United Kingdom, it is being issued to persons who are professional clients or are exempt investors in accordance with the FSMA 2000 (Promotion of Collective Investment Schemes) Exemptions Order) 2005. This document does not purport to be all inclusive or to contain all the information which prospective investors may require. The approval by CIL is limited to the information contained in this document.

This document is not an advertisement and it is not intended for public use or distribution. This document does not constitute advice on the merits of buying and selling an investment nor does it form part of any offer to issue or sell, nor any solicitation of any offer to subscribe for or purchase, shares in any fund managed by Coronation, nor shall it or the fact of its distribution form the basis of, or be relied upon in connection with, any contract for shares in any fund. It is recommended that an investor first obtain the appropriate legal, tax, investment or other professional advice and formulate an appropriate investment strategy that would suit their individual risk profile prior to acting upon such information. Past performance is not necessarily a guide to future performance.